43 Results for "

gravis

" in MedChemExpress (MCE) Product Catalog:
Products (43)

43 Results for "gravis" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P99037
CAS No.: 2211985-36-1
Synonyms: M281

Target:  

Fc Receptor (FcR)

Research Areas:  

Inflammation/Immunology

Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N5077
CAS No.: 18696-26-9
Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-139588
CAS No.: 2086178-00-7
Purity:  98.61%
Synonyms: ALXN2050; ACH 0145228; ACH-5228
Vemircopan (ALXN2050) is an orally active complement factor D (FD) inhibitor. Vemircopan can be used in the research of diseases such as myasthenia gravis, lupus nephritis, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0450
CAS No.: 7431-77-8
Sinapine thiocyanate is an alkaloid isolated from seeds of the cruciferous species. Sinapine thiocyanate exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine thiocyanate is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99113
CAS No.: 1299440-37-1
Synonyms: MEDI-551
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0423
CAS No.: 114-80-7
Synonyms: Eustigmin bromide; Neoserine bromide
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

Neostigmine (Eustigmin) Bromide is an orally active and reversible cholinesterase inhibitor that acts on myasthenia gravis to prolong and intensify the muscarinic and nicotinic effects of acetylcholine. Neostigmine Bromide can be used in anesthesia to reverse the neuromuscular blockade produced by competitive neuromuscular blockers .
loading...
    loading...
Cat. No.: HY-147305
CAS No.: 1821402-21-4
Synonyms: ARGX-113
Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research .
loading...
    loading...
Cat. No.: HY-P990706
CAS No.: 2490217-42-8
Synonyms: ALPN-303

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Povetacicept (ALPN-303) is an engineered Fc fusion protein containing the TACI domain, and acts as a dual APRIL/BAFF antagonist. The Kd value of Povetacicept for human BAFF is 59.3 pM, while its Kd value for human APRIL is 1.00 pM. Povetacicept reduces the activation, proliferation, differentiation and survival of B cells, and inhibits the production of immunoglobulins and autoantibodies. Povetacicept can be used in research related to autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus, lupus nephritis and myasthenia gravis .
loading...
    loading...
Cat. No.: HY-P99009
CAS No.: 2187430-05-1
Synonyms: RVT-1401; HBM9161; IMVT-1401

Target:  

Fc Receptor (FcR)

Research Areas:  

Inflammation/Immunology

Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
loading...
    loading...
Cat. No.: HY-B0882
CAS No.: 116-38-1
Edrophonium chloride is a short-acting acetylcholinesterase (AChE) inhibitor. Edrophonium chloride has Ki values of 0.2, 0.2, and 0.4 μM and IC50 values of 0.2, 0.05, and 0.5 μM for AChE in human erythrocytes, purified calf forebrain, and purified octopus brain, respectively. Edrophonium chloride can be used to detect early digitalis toxicity and in the study of myasthenia gravis .
loading...
    loading...
Cat. No.: HY-P5766
CAS No.: 663154-30-1
Target:  

nAChR

AChRα(97-116) is a synthetic peptide corresponding to the 97-116 region of the rat acetylcholine receptor α-subunit, and also an inducer of autoimmune diseases. AChRα(97-116) can be used in studies related to experimental autoimmune myasthenia gravis .
loading...
    loading...
Cat. No.: HY-P99365
CAS No.: 1803171-55-2
Synonyms: ALXN1210

Target:  

Complement System

Research Areas:  

Metabolic Disease

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
loading...
    loading...
Cat. No.: HY-P991127
CAS No.: 2922766-89-8
Synonyms: DNTH103

Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Claseprubart (DNTH103) is an inhibitor targeting C1s of the complement system and an inhibitor of the C1 component of the complement cascade. Claseprubart is in phase 2 clinical evaluation. Claseprubart has application potential in research related to multifocal motor neuropathy and generalized myasthenia gravis .
loading...
    loading...
Cat. No.: HY-119577
CAS No.: 15876-67-2
Purity:  ≥99.0%
Synonyms: Distigmine dibromide
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase agents, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder .
loading...
    loading...
Cat. No.: HY-100919
CAS No.: 115-79-7
Purity:  96.18%
Synonyms: WIN 8077 chloride
Target:  

Cholinesterase (ChE)

Research Areas:  

Others

Ambenonium (WIN 8077) chloride is an orally active and reversible inhibitor of Acetyicholinesterase (AChE) with high affinity. Ambenonium chloride inhibits human AChE with an IC50 value of 0.7 nM (hAChE) .
loading...
    loading...
Cat. No.: HY-158183
CAS No.: 2354321-33-6
Purity:  99.60%
Target:  

Chloride Channel

Research Areas:  

Neurological Disease

NMD670 is an orally active inhibitor of skeletal muscle specific chloride channel ClC-1 with an EC50 of 1.6 μM. NMD670 enhances neuromuscular transmission and improves muscle contraction and strength. NMD670 can be used in the study of muscle weakness and muscle fatigue .
loading...
    loading...
Cat. No.: HY-P99638
CAS No.: 2456407-94-4
Synonyms: ALXN-1720

Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis .
loading...
    loading...
Cat. No.: HY-P5766A
Target:  

nAChR

Research Areas:  

Metabolic Disease

AChRα(97-116) TFA, a peptide, can be used to induce experimental autoimmune myasthenia gravis (EAMG)
loading...
    loading...
Cat. No.: HY-P990302

Target:  

nAChR

Research Areas:  

Inflammation/Immunology

Anti-Human/Rat/Fish AChR Antibody (Mab35) is an anti-human/rat/fish AChR IgG1 monoclonal antibody. Anti-Human/Rat/Fish AChR Antibody (Mab35) can attack the AChR of neuromuscular junctions. Anti-Human/Rat/Fish AChR Antibody (Mab35) can be used for the construction of myasthenia gravis models .
loading...
    loading...
Cat. No.: HY-122140
CAS No.: 795316-16-4
Purity:  99.72%
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

ACG548B (compound 24) is a potent inhibitor of acetyl- and butyrylcholinesterase (AChE and BChE) with IC50s of 1.78 and 0.496 μM, respectively. ACG548B has higher AChE affinity and selectivity over BChE and ChoK (choline kinase). ACG548B can be uesd for the study of myasthenia gravis and neuromuscular blockade .
loading...
    loading...